Prof. Antoni Ribas, will reveal his findings on this question during ISCORT Congress 2020
Antoni Ribas lecture at ISCORT congress
THE SCIENCE OF CANCER IMMUNOTHERAPY
RESISTANCE TO IMMUNOTHERAPY
Ribas is conducting several clinical trials of cutting-edge treatments including both immunotherapies and targeted stem cell-based therapies. In 2017, he launched a first-of-its-kind trial that involves genetically engineering blood-forming stem cells to produce cancer-fighting T cells to treat melanomas and sarcomas and later multiple myeloma. The clinical trial involves a dual approach intended to provide patients with both short and long-term immune responses to their cancer. This is accomplished by giving patients modified blood-forming stem cells and modified mature T cells in a single transplant. Upon transplant, the modified mature T cells begin fighting the cancer immediately, while the modified blood-forming stem cells work to generate an on-going supply of new modified T cells, resulting in a lasting immune response to the cancer1. Ribas is also leading clinical trails in the field of Nanoparticle-siRNA therapeutics2.1Chao Ma, Ann F Cheung, Thinle Chodon, Richard C Koya, Zhongqi Wu, Charles Ng, Owen N. Witte, David Baltimore, Bartosz Chmielowski, James S. Economou, Begonya Comin-Anduix, Antoni Ribas*, James R. Heath*. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. *equal contribution as corresponding and senior authors. Cancer Discovery 2013 Apr; 3 (4): 418-29.
Ribas studies how the immune system responds to and develops resistance to immunotherapies, and how combination therapies may be used to overcome treatment resistance. One such treatment the Ribas lab is evaluating combines pembrolizumab with a targeted therapy that blocks a protein that leads to mutations in the BRAF gene.The BRAF gene makes a protein called B-RAF, which is involved in cell communication and growth. When BRAF genes are mutated, they can increase the growth and spread of cancer cells; approximately one‐half of all patients with melanoma have mutations in the BRAF gene3-5*.* The BRAF gene makes a protein called B-RAF, which is involved in cell communication and growth. When BRAF genes are mutated, they can increase the growth and spread of cancer cells; approximately one‐half of all patients with melanoma have mutations in the BRAF gene.
Ribas and his team utilize molecular imaging technology such as PET scans to investigate and understand precisely how novel immunotherapies work on a molecular level. They aim to use these technologies to guide and evaluate new therapeutic strategies for melanoma6,7.6 Escuin-Ordinas H, Elliott MW, Atefi M, Lee M, Ng C, Wei L, Comin-Anduix B, Montecino-Rodriguez E, Avramis E, Radu C, Sharp LL, Ribas A. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. J Immunother Cancer. 2013 Aug 27;1:14.
Antoni Ribas has been awarded the sixth American Association of Cancer Research–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. Dr. Ribas is being recognized for his leadership in the development of new cancer immunotherapies. His research has been aimed at gaining a better understanding of immunotherapies to treat cancer with reduced toxicity for patients with melanoma. He led the clinical program that demonstrated the effectiveness of pembrolizumab (Keytruda).